Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00. Following the completion of the sale, the president now directly owns 2,901,138 shares of the company’s stock, valued at $30,432,937.62. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.

Gyre Therapeutics Price Performance

Gyre Therapeutics stock opened at $11.74 on Wednesday. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $26.37. The business has a fifty day moving average of $11.12 and a two-hundred day moving average of $12.57.

Institutional Trading of Gyre Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter worth about $47,000. Barclays PLC grew its holdings in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth approximately $123,000. Renaissance Technologies LLC purchased a new position in Gyre Therapeutics in the 2nd quarter valued at approximately $166,000. Finally, Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics during the third quarter worth $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.